Blink index as a response predictor of blepharospasm to botulinum neurotoxin-A treatment

Clinical implications of genetic polymorphisms in blepharospasm

The possible genetic variants associated with blepharospasm (BSP) and facial dystonia have been investigated. Although genetic variants associated with BSP have been extensively studied, the contribution of single-nucleotide polymorphisms towards this condition remains poorly understood. In addition, the etiology of BSP remains to be fully elucidated. Therefore, the present study aimed to assess the role of polymorphisms in the torsin 1A (TOR1A), dopamine receptor D (DRD)2 and DRD5 genes in South Korean patients with BSP. Furthermore, the role of genetic variants of these three aforementioned genes was investigated. A prospective case-control study was established, where 56 patients with BSP and 115 healthy controls were recruited at the Department of Ophthalmology of CHA Bundang Medical Center (Seongnam, South Korea) using single nucleotide polymorphisms analysis by real-time PCR. The TOR1A rs1182CC/DRD5 rs6283TC genotype combination was found to be associated with decreased BSP risk [adjusted odds ratio (AOR), 0.288; P=0.013]. DRD5 rs6283 was observed to be associated with the periocular type of BSP in the co-dominant (for the TC genotype; AOR, 0.370; P=0.029) and dominant models (AOR, 0.406; P=0.029). The recessive model of TOR1A rs1801968 (AOR, 0.245; P=0.030), and the recessive (AOR, 0.245; P=0.029) and over-dominant models (AOR, 2.437; P=0.019) of DRD2 rs1800497 were found to be associated with superior responses to botulinum neurotoxin A (BoNT) treatment. By contrast, dominant (AOR, 0.205; P=0.034) and additive (AOR, 0.227; P=0.030) models of DRD5 rs6283 were associated with poor responses to BoNT treatment. To conclude, these results suggested that DRD2 rs1800497 can confer genetic susceptibility to BSP responses to BoNT treatment, whereas the TOR1A rs1182CC/DRD5 rs6283TC genotype combination appeared to contribute to the association with BoNT efficacy in BSP.

Assessing blink dynamics with non-noticeable method

PURPOSE

The purpose of the study was to demonstrate the feasibility of blink dynamics with a contactless, non-noticeable method without any visible light being reflected to the participant's eye by the device, and to investigate the blink dynamics parameters in 39 participants whose blink dynamics were examined with this method. It was also aimed to explain the potential of corneal topography devices for non-noticeable blink dynamics and elucidate some tips to device manufacturers to make them practical.

METHODS

A one-minute real-time video image in the meibography module of the scheimpflug camera-based corneal topography device was recorded in the slow motion mode of the mobile phone. Detailed analysis of blink dynamics was made by advancing the video images manually at 10 ms intervals. Lid Closing Time (LCT), Lid Opening Time (LOT), third Interblink Interval times (IBI(3)), fifth Interblink Interval times (IBI(5)), Number of Blinks Per Minute (NoB), Number of Complete Blinks Per Minute (NoCB), Number of Incomplete Blinks Per Minute (NoICB) were investigated.

RESULTS

The average NoB, NoCB, and NoICB (blinks/minute) with ± standard deviation (SD) values were found to be 22.9 ± 14.4; 14.5 ± 12.4 and 8.4 ± 8, respectively. The average IBI(3) time(seconds) with ± SD was measured as 3.4 ± 4.5. The average IBI(5) time (seconds) with ± SD was 3.9 ± 3.7 The average LCT time (milliseconds) with ± SD was found to be 91.9 ± 36.9 in the 4 different blinks analyzed. The average LOT time (milliseconds) with ± SD was found to be 582.6 ± 196.5 in the 3 different blinks analyzed.

CONCLUSIONS

Blink dynamics can be examined in detail with corneal topography devices in a non-contact, no visible light, and most importantly, non-noticeable manner. Existing video imaging modules of corneal topography devices have the potential to investigate blink dynamics. It is anticipated that the clinical use of blink dynamics, which can be performed practically, will increase, particularly in the monitoring of ocular surface and neurological diseases.

Quantitative assessment of botulinum toxin injection on blink rate in blepharospasm

PURPOSE

To objectively measure the blink rate in patients with blepharospasm managed by botulinum toxin type-A injections.

METHODS

In this prospective, non-interventional case series, the complete blink rates of subjects were measured before incobotulinumtoxina injection and at follow-up within 4 weeks using slow-motion video-taping. Additionally, subjects graded the frequency of blinking, the severity of light-sensitivity, and the severity and frequency of dry eye symptoms on a categorical visual analog scale. The results are reported as median (range).

RESULTS

Ten subjects were enrolled, with nine females. The total duration of treatment was 70 (5-116) months with total of 27.5 (2-51) injections. The subjects were grouped as short-time (<52w) or long-time (>52w) treatments. The median age, follow-up time, and injected doses were 73.5 (49-81) years, 21 (14-28) days, and 38 (8-47) units, respectively, with no significant difference between groups. The total complete blinks per minute before incobotulinumtoxina injection was 39 (23-64) which decreased to 18.5 (1-60) at follow-up (p = 0.004). The average change in complete blink rate was -67.4 ± 23.7% in long-time and -45.2 ± 31.2% in short-time groups (mean ± SD, p = 0.01). The total self-graded frequency of blinking and light-sensitivity decreased significantly at follow-up (p = 0.004, p = 0.047, respectively). Similar patterns of subject reported grades were seen in both groups.

CONCLUSION

Videotaping is a low-cost method for objective measurement of blink rate in blepharospasm patients after incobotulinumtoxina injection. There was a significant reduction in blink rate after incobotulinumtoxina injections with higher percentage of change in the long-time treatment group. Incobotulinumtoxina injection also significantly improves subjective photophobia.

Dry eye disease and blinking behaviors: A narrative review of methodologies for measuring blink dynamics and inducing blink response

Dry eye disease (DED) is a leading cause of ophthalmology clinical encounters with prevalence ranging from 8.7% to 64% in various populations. Blinking is an endogenous process to refresh the tear film, clear debris and maintain quality vision. Altered blinking behavior is a common feature of DED and is implicated in the pathology of the disease. However, lack of a comprehensive review on the relationship between altered blinking behavior and DED is notable in the literature. Blinking behavior may be an effect of DED due to an unstable tear film sensitizing a motor response or be its cause due to destabilization of the tear film in conditions such as benign essential blepharospasm. In this comprehensive review, we summarize the current models and theories of tear film dynamics and blinking behavior to better understand their connection to DED and introduce contemporary technologies and measurement tools used in the evaluation and induction of blinking behavior. We also describe future directions of research to better understand the relationship between DED and blinking and explore therapies that address the abnormal blinking component of DED.

Recovery of the Ratio of Closure Time during Blink Time in Lacrimal Passage Intubation

(1) Background: We aim to find a novel blink parameter in nasolacrimal duct obstruction (NDO) patients and analyze parameters that could reflect subjective symptoms and objective indicators at the same time through a blink dynamic analysis. (2) Methods A retrospective study was conducted with 34 patients (48 eyes) who underwent lacrimal passage intubation (LPI) and 24 control groups (48 eyes). All patients' blink patterns were measured using an ocular surface interferometer before and after LPI, including total blink (TB) and partial blink (PB) and the blink indices blink time (BT), lid closing time (LCT), closure time (CT), lid opening time (LOT), interblink time (IBT), closing speed (CS) and opening speed (OS). The tear meniscus height (TMH) was measured, and the questionnaire "Epiphora Patient's Quality of Life (E-QOL)," which includes daily activity restriction as well as static and dynamic activities, was completed. (3) Results: Compared to CT and the ratio of CT during BT (CT/BT) in control (89.4 ± 20.0 msec, 13.16%), those in NDOs were longer (140.3 ± 92.0 msec, 20.20%) and were also related to TMH. After LPI, CT and CT/BT were recovered to 85.4 ± 22.07 msec, 13.29% (p < 0.001). CT and CT/BT showed a positive correlation with the E-QOL questionnaire score, particularly with dynamic activities. (4) Conclusions: CT and CT/BT, which are objective indicators associated with subjective symptoms of patients, are considered new blink indices for the evaluation of NDO patients with Munk's score.

Blink index as a response predictor of blepharospasm to botulinum neurotoxin-A treatment

PURPOSE

We investigated the blink profiles and blink index using ocular surface interferometer in the patients with blepharospasm (BSP) and identified points to consider predictive factor after BSP treatment.

METHODS

In total, 117 eyelids of 59 elderly patients and 20 eyelids of 10 age-matched control group were studied. All BSP patients applied botulinum toxin-A (BoNT-A) injection for treatment of BSP. An ocular surface interferometer (LipiView; TearScience, Morrisville, NC, USA) was used to measure blink profile and blink index; total and incomplete blinks/20 s, and the partial blink ratio (PBR). Eyelid blink time (including lid closing time, closure time, lid opening time), interblink times (IBT), closing speeds (OS), and opening speeds (OS) were analyzed using 600 blinks recorded over 20 s.

RESULTS

Total blink rate was significantly higher in BSP patients compared to the age-matched control group (p = .029) but other time-related and speed-related index including interpalpebral fissure, PBR, blink time, closure time (CT), interblink time, CS, and OS were not significantly different. In the responder of BSP patients, the average age was higher, CT was shorter, CS was faster than nonresponder (age; p = .016, CT; p < .001, CS; p = .042).

CONCLUSION

The blink index by analyzing the blink profile using ocular surface interferometer, and this blink index may be used as a predictive factor for evaluating the clinical response after BoNT-A injection in blepharospasm patients.